2023-04-28
Redeye Orphan Drug Day
CEO Magnus Corfitzen presents at Redeye Orphan Drug Day
Presentations & Articles
2023-03-30
HC Andersen – Orviglance commercial opportunity and progress towards launch
Deputy Chief Executive Officer & CCO presents at HC Andersen
2023-02-16
HC Andersen – Q4 2022 highlights and Q&A
Chief Executive Officer presents at HC Andersen - Q4 2022 highlights and Q&A
2022-09-13
ABGSC Investor Day
CEO Magnus Corfitzen presents at ABG Investor Day
2022-05-31
HC Andersen – Oncology Seminar
Chief Executive Officer presents at HC Andersen Oncology Seminar
2022-05-19
Erik Penser Bank – Company Day
Chief Executive Officer presents at Erik Pensers Company Day
2022-04-27
Redeye Orphan Drug Day
Chief Medical Officer, Carl Bjartmar presents at Redeye Orphan Drug Day
2022-04-08
Oncoral featured in the journal International Pharmaceutical Industry
In the April edition of the International Pharmaceutical Industry Journal, you can read about the science and our work to improve the outcomes for gastric cancer patients through our innovative daily oral chemotherapy drug candidate, Oncoral (page 30-33)
2022-03-29
New Market Research Shows Strong Support for Orviglance
New independent market research shows that 84% of healthcare professionals will likely use Orviglance® for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function. The research confirms the clear unmet need for an effective alternative to unenhanced MRI and a safe alternative to gadolinium contrast agents.
2022-03-03
A New Approach to Imaging Focal Liver Lesions in Patients With Reduced Kidney Function
A New Approach to Imaging Focal Liver Lesions in Patients With Reduced Kidney Function
2022-02-24
Erik Penser Bank – Life Science day
Chief Commercial Officer Julie Waras Brogren presents at Erik Pensers Life Science day
2022-01-31
Ascelia Pharma – Aktiedagen in Lund 2022
Chief Commercial Officer presents at Aktiedagen in Lund
2022-01-20
Redeye Fight Cancer Seminar 2022
VP of R&D Andreas Norlin presents at Redeye Fight Cancer Seminar
2021-12-07
HC Andersen Capital seminar – Re-read Study Orviglance vs. Gadolinium
CEO Magnus Corfitzen presents results from the re-read study vs. a gadolinium contrast agent (presentation in Danish)
2021-11-25
Erik Penser Bank – Company day
CEO Magnus Corfitzen presents at Erik Penser company day.
2021-11-11
Redeye Life Science Day 2021
Ascelia Pharma CEO Magnus Corfitzen presents at Redeye Life Science Day.
2021-11-04
Q3 2021 Financial Presentation
The Executive Managment in Ascelia Pharma presents a business update and the quarterly results
2021-10-06
HC Andersen/Nordea Small & Mid Cap Seminar
CEO Magnus Corfitzen presents at the Danish HC Andersen/Nordea Small & Mid cap seminar (presentation in Danish)